molecules of the year


In 2020 the Drug Hunter site highlighted >150 “molecules of the month” whose structures or stories were typically published for the first time. They were selected from thousands of research articles, published by leading institutions around the world. It was incredibly hard to narrow down the selection to just one molecule from each month, and it’s agonizing to leave so many amazing stories off this list, but here are 12 molecules from 2020 that our community would likely all agree we learned a lot from. The molecules were selected based on a range of factors, from clinical and commercial timeliness (such as Mirati’s market-moving KRAS inhibitor from April) to mechanistic proof of concept (such as GSK’s RIPK2 degrader with prolonged PD) to interesting modalities (such as Novartis’s reversible-covalent aldehyde FGFR4 inhibitor) to overcoming a brutal drug discovery campaign against a difficult mechanism of action (such as Gilead’s HIV capsid inhibitor).

nominate a molecule

Encountered an interesting new molecule? Let your community know!

become a reviewer

Get sneak previews of upcoming molecules and share your knowledge and expertise with the drug discovery community.

past molecules of the month

Check out previous selections below.

molecules of the year nominees

Previous selections for Drug Hunter’s Molecule of the Year below.

hall of fame
molecules of the year

Previous selections for Drug Hunter’s Molecule of the Year below.

ask your company about a Drug Hunter membership

Member Benefits

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Support new content and build your industry community